Certified breast centres are requested to recruit patients in prospective clinical trials.
Currently open and planned studies, coordinated by the following organisations:
- International Breast Cancer Study Group (IBCSG)
- European Organisation for Research and Treatment of Cancer (EORTC)
Please send information about new studies to: email@example.com
Management of low risk ductal carcinoma in situ (low-risk DCIS): a randomized, multicentre, non-inferiority trial, between standard therapy approach versus active surveillance.
A phase II study of Palbociclib plus Fulvestrant vs Fulvestrant plus Placebo for pretreated patients with ER+/HER2- metastatic Breast Cancer; Palbociclib in molecularly characterized ER-Positive/HER2 negative metastatic Breast Study
IBCSG 48-14 POSITIVE
A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy.
IBCSG 51-14 AURORA
Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
Efficacy of a new kind of chemotherapy for the treatment of breast cancer
IBCSG 50-14 OLYMPIA
Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors
Tailored AXIllary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)
IBSCG 55-17 TOUCH
To Reduce the Use of Chemotherapy in Elderly Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
Activity Program During Aromatase Inhibitor Therapy
Bureau du label de qualité
Ligue suisse contre le cancer
Case postale 8219